A United Nations agency has urged the pharmaceutical company Gilead Sciences to lower the price of the long acting antiviral treatment lenacapavir following the US Food and Drug Administration (FDA)’s ...

Gilead's FDA-approved Yeztugo, a twice-yearly injectable HIV PrEP, showed near-perfect trial efficacy but faces backlash over ...

The US FDA has approved lenacapavir, a biannual injection by Gilead, to prevent HIV, potentially revolutionizing the fight against the epidemic.

The United States Food and Drug Administration (FDA) has approved long-acting injectable lenacapavir for HIV prevention. The ...

The US Food and Drug Administration (FDA) has approved use of the vaccine Yeztugo, manufactured by Gilead Sciences, is an anti-HIV drug.

FDA Approves Yeztugo as First Twice-Yearly Injectable HIV Prevention Option in the U.S. Clinical Trials Show Near-Perfect ...

US Congress member Marjorie Taylor Greene purchased shares of Adobe, Netflix, Snowflake, ServiceNow, NextEra Energy, and Gilead Sciences on 6th June.

General, Winnie Byanyima, has called for a drastic and transparent reduction in the cost of lenacapavir, a twice-yearly ...

A twice-yearly injectable drug for the prevention of HIV infection has been approved by the United States’ Food and Drug ...

The FDA has approved Yeztugo, a twice-yearly HIV injection by Gilead shown to virtually eliminate new infections.

Gilead Sciences’ Yeztugo receives nod; the first and only US FDA-approved HIV prevention option offering 6 months of protection: Foster City, California Friday, June 20, 2025, 1 ...

The Food and Drug Administration has approved a highly effective new HIV prevention medication, known as Yeztugo. In clinical ...